Amundi Acquires 11,548 Shares of Merit Medical Systems, Inc. (NASDAQ:MMSI)

Amundi raised its position in Merit Medical Systems, Inc. (NASDAQ:MMSI - Free Report) by 9.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 129,933 shares of the medical instruments supplier's stock after purchasing an additional 11,548 shares during the quarter. Amundi owned about 0.22% of Merit Medical Systems worth $12,752,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in MMSI. FMR LLC boosted its holdings in shares of Merit Medical Systems by 70.1% in the third quarter. FMR LLC now owns 1,577,246 shares of the medical instruments supplier's stock valued at $155,879,000 after acquiring an additional 649,799 shares in the last quarter. Raymond James Financial Inc. bought a new position in shares of Merit Medical Systems in the fourth quarter valued at approximately $48,926,000. Bryn Mawr Capital Management LLC bought a new position in shares of Merit Medical Systems in the fourth quarter valued at approximately $36,057,000. Two Sigma Advisers LP boosted its holdings in shares of Merit Medical Systems by 218.9% in the third quarter. Two Sigma Advisers LP now owns 445,500 shares of the medical instruments supplier's stock valued at $44,029,000 after acquiring an additional 305,800 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its holdings in shares of Merit Medical Systems by 85.6% in the third quarter. JPMorgan Chase & Co. now owns 575,946 shares of the medical instruments supplier's stock valued at $56,921,000 after acquiring an additional 265,648 shares in the last quarter. Institutional investors and hedge funds own 99.66% of the company's stock.

Remove Ads

Analyst Ratings Changes

Several research analysts have recently issued reports on the stock. Barrington Research decreased their price objective on shares of Merit Medical Systems from $115.00 to $111.00 and set an "outperform" rating for the company in a report on Wednesday, February 26th. Needham & Company LLC decreased their price objective on shares of Merit Medical Systems from $122.00 to $116.00 and set a "buy" rating for the company in a report on Wednesday, February 26th. Piper Sandler restated an "overweight" rating and set a $116.00 target price (up from $114.00) on shares of Merit Medical Systems in a report on Wednesday, January 29th. Wells Fargo & Company reduced their target price on shares of Merit Medical Systems from $120.00 to $117.00 and set an "overweight" rating for the company in a report on Wednesday, February 26th. Finally, Canaccord Genuity Group reduced their target price on shares of Merit Medical Systems from $128.00 to $127.00 and set a "buy" rating for the company in a report on Wednesday, February 26th. Two equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, Merit Medical Systems presently has an average rating of "Moderate Buy" and a consensus price target of $110.78.

Merit Medical Systems Stock Down 0.7 %

MMSI stock traded down $0.74 during midday trading on Tuesday, reaching $99.95. The company had a trading volume of 490,080 shares, compared to its average volume of 418,006. Merit Medical Systems, Inc. has a 1 year low of $70.70 and a 1 year high of $111.45. The company has a current ratio of 5.36, a quick ratio of 3.82 and a debt-to-equity ratio of 0.57. The company has a market capitalization of $5.88 billion, a P/E ratio of 49.00, a PEG ratio of 2.34 and a beta of 0.91. The company has a 50 day moving average of $103.61 and a two-hundred day moving average of $100.68.

Insiders Place Their Bets

In other Merit Medical Systems news, insider Brian G. Lloyd sold 30,000 shares of the stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $102.90, for a total value of $3,087,000.00. Following the completion of the sale, the insider now owns 38,945 shares in the company, valued at $4,007,440.50. This represents a 43.51 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Fred P. Lampropoulos sold 31,320 shares of the stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $103.86, for a total transaction of $3,252,895.20. Following the completion of the sale, the chief executive officer now owns 1,086,028 shares of the company's stock, valued at approximately $112,794,868.08. The trade was a 2.80 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 109,132 shares of company stock worth $11,139,521 in the last quarter. 3.70% of the stock is currently owned by corporate insiders.

Merit Medical Systems Company Profile

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.